Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
221
resultados
Última actualización
24/10/2026 [07:05:00]
Resultados 100 a 125 de 221
Resumen de: WO2026217473A2
Provided herein are nanostructures comprising a lipophilic component comprising a peptide segment coupled to a hydrophobic segment, an amphiphilic small molecule (ASM), and a metal cation. Also provided herein are compositions comprising the nanostructures, methods of preparation, and methods of administration.
Resumen de: WO2026215393A1
The present invention relates to ionizable lipids for use in lipid nanoparticles, lipid nanoparticle formulations comprising these ionizable lipids, alone or in combination with other lipids and/or polymers. The lipid nanoparticles formulations may be formulated with nucleic acids for their delivery to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration.
Resumen de: WO2026214846A1
The present invention relates to a plurality of nanoparticles comprising crystalline aprepitant. The present invention also relates to a composition comprising the plurality of nanoparticles, a process for producing the composition, and to the plurality of nanoparticles or composition for use in medical methods.
Resumen de: AU2026238051A1
The present disclosure relates to ionisable lipids of Formula I and related structures that comprise a headgroup, core, and hydrophobic substituents. The lipids are capable of forming lipid particles, including lipid nanoparticles (LNPs), in combination with additional lipids such as neutral lipids, charged lipids, structural lipids, or PEGylated lipids. The lipid particles are suitable for delivery of therapeutic agents, including polynucleotides, peptides, antibodies, and small molecules. Compositions comprising the ionisable lipids and methods of forming and using the lipid particles are also provided. ep e p
Resumen de: AU2026238052A1
The present disclosure relates to ionisable lipids of Formula I and related structures that comprise a headgroup, core, and hydrophobic substituents. The lipids are capable of forming lipid particles, including lipid nanoparticles (LNPs), in combination with additional lipids such as neutral lipids, charged lipids, structural lipids, or PEGylated lipids. The lipid particles are suitable for delivery of therapeutic agents, including polynucleotides, peptides, antibodies, and small molecules. Compositions comprising the ionisable lipids and methods of forming and using the lipid particles are also provided. ep e p
Resumen de: US20260315502A1
0000 The invention relates generally to a cryogenic process for making cannabinoid nanoparticles and compositions made thereby.
Resumen de: WO2026215899A1
The present invention aims to develop highly efficient lipid-based, drug/gene delivery nano- formulations using glycolipids (GL) and phospholipids (PL) isolated from crude rice bran gum obtained from rice bran oil refinery. Present invention shows that formulations carrying cationic lipid such as D1 with or without PL and cholesterol showed greater penetration through the blood-brain-barrier compared to standard DOPC : Chol formulation. Further supplementation of minute quantity of GL to each formulation enhanced the permeation and retention of respective nano-formulations in mice brains. Moreover, formulations carrying both GL & PL and with or without D1 showed efficient gene transfection in brain cancer cells. Additionally, GL/PL carrying formulations with or without D1 encapsulating hydrophobic anticancer drug, docetaxel showed efficient antitumor effect. Replacing synthetic lipids with natural mixtures of GL/PL reduces cost of production, increases biological output as well as provide value-addition to rice bran gums, helping in overall sustainability of the industry.
Resumen de: WO2026214081A1
Provided are a pH-responsive block copolymer nanoparticle, a preparation method therefor and the use thereof. The pH-responsive block copolymer nanoparticle is formed by connecting poly(N,N-dimethylaminoethyl methacrylate) and poly(2-(diisopropylamino)ethyl methacrylate) via a covalent bond. On the basis of a polymerization-induced self-assembly method, a pH-responsive nanoparticle with a controllable morphology and size is prepared under high solid content conditions by means of regulating the molecular composition of the block copolymer and the ratio of mixed polar solvents in the external environment. The pH-responsive block copolymer nanoparticles are used for preparing a biomedical drug delivery system.
Resumen de: US20260315525A1
0000 A method of treating cancer cells includes contacting cancer cells with ternary metal oxide nanoparticles to induce cell death of the cancer cells. The ternary metal oxide nanoparticles include a zinc oxide matrix doped with terbium and erbium. The terbium is present in an amount of 0.5 to 10 atomic percent (at. %), and the erbium is present in an amount of 0.5 to 10 at. %. Atomic percent is based on the total atom count of the zinc, terbium, and erbium. The erbium replaces zinc within the zinc oxide matrix. The ternary metal oxide nanoparticles have an average particle size of 22 to 32 nm.
Resumen de: US20260315405A1
Chitosan-based nanocapsule system for use in the prophylactic and/or therapeutic treatment of an infection caused by an enveloped virus. The present disclosure refers to the medical field. Particularly, it refers to a chitosan-based nanocapsule system for use in the prophylactic treatment of an infection caused by a respiratory pathogen, preferably an enveloped respiratory virus, wherein the nanocapsule system is administered intranasally.
Resumen de: US20260315537A1
0000 The present disclosure includes compositions and methods of treating cancerous growth. For example, methods of the present disclosure may include administering a first nanoparticle composition to a subject having the cancerous growth, administering a second nanoparticle composition to the subject having the cancerous growth, and/or administering CAR-T cells to the subject having the cancerous growth. The first nanoparticle composition, the second nanoparticle composition, or both, may include tumor necrosis factor alpha and/or interferon gamma.
Resumen de: AU2025254683A1
A lipid nanoparticle formulation having remarkably improved stability and a preparation method therefor. The lipid nanoparticle formulation comprises a pharmaceutically acceptable buffer solution, lipid nanoparticles and a nucleic acid encapsulated in the lipid nanoparticles.
Resumen de: AU2025248899A1
Provided herein are compositions and associated methods for CH-based nano-carriers for therapeutic agents and their applications, a multi-step method for the synthesis of the pharmacologically stable and multifunctional CH-based nano-carriers, effectively carrying therapeutic or theranostic radioactive metal isotope, anionic immunotherapeutic agent, or other anionic therapeutic agents used as therapeutic drugs, including the one of "combined radio-and adjuvant immuno-therapy" for cancer treatment.
Resumen de: US20260317270A1
0000 The present disclosure relates generally to lipids, lipid nanoparticle formulations, and methods of using the same for delivering nucleic acids, such as mRNA.
Resumen de: AU2025252440A1
The present disclosure provides lipid nanoparticles that are particularly beneficial in inducing an immune response in a subject, particularly by stimulating CD8+ T cells associated with protein or protein fragments of interest. The lipid nanoparticles can have a negative zeta potential and/or particular configurations and/or relative amounts of a phospholipid, an ionizable lipid, and a conjugated lipid. The disclosure also provides vaccines, other pharmaceutical compositions, and methods including the provided lipid nanoparticles.
Resumen de: AU2025374772A1
In accordance with at least one aspect of this disclosure, there is provided a small zwitterionic multimeric targeted anti-cancer drug which effectively addressed tumor cell heterogeneity and off-target/non-specific binding and uptake. The small zwitterionic multimeric targeted anti-cancer drug includes a nexus, three different targeting ligands conjugated to the nexus, a payload of a zwitterionic diagnostic or therapeutic agent, and zwitterionic flexible linkers connecting each of the three different targeting ligands and the pay load to the nexus.
Resumen de: AU2025251559A1
Described herein are methods of synthesizing ionizable amine lipids, such as Lipid A: with increased overall purity, process robustness and an applied impurity control strategy, leading to a substantially pure Lipid A product. Intermediate compounds and methods of synthesizing intermediate compounds are also described.
Resumen de: US20260315431A1
0000 The present disclosure provides for compositions including aurone-based small molecules encapsulated into hydrogel particles. The disclosure also provides for pharmaceutical compositions including the hydrogel encapsulated aurones and methods of use of the hydrogel encapsulated aurones. Compounds and pharmaceutical compositions of the present disclosure can be used in combination with one or more other therapeutic agents for treating biofilms, such as Streptococcus mutans (S. mutans) biofilm, dental caries, and other diseases.
Resumen de: US20260315402A1
The disclosure features novel lipid nanoparticle formulations and use thereof. Lipid nanoparticles include cationic ionizable lipids, helper lipids, sterols, and conjugated lipids. Lipid nanoparticles further including therapeutics and/or prophylactics such as DNA are useful in the delivery of therapeutics and/or prophylactics to cells or organs (e.g., mammalian cells or organs) to, for example, regulate polypeptide, protein, or gene expression.
Resumen de: US20260315581A1
0000 Provided herein are compositions, polynucleotides (e.g., mRNAs), vaccines, and methods for the treatment and prevention of skin infection and/or systemic infection by Candida auris. In certain embodiments, the treatment and prevention include generating an immune response in a subject against at least a portion of Surface Colonization Factor (SCF1) from Candida auris (e.g., SEQ ID NO: 16). In some embodiments, treatment and prevention employs agents that inhibit SCF1 mRNA and/or the biotic and abiotic surface attachment function of SCF1.
Resumen de: WO2026217014A1
The group of inventions relates to chemistry, biotechnology and pharmaceutics, and more particularly to a method of packing low molecular weight compounds into biological micro- and nanoparticles, as well as to loaded nanoparticles produced using said method, a pharmaceutical composition containing said loaded nanoparticles, and the use of said loaded nanoparticles. The method includes the steps of: (a) concentrating initial biological nano- and/or microparticles in an isotonic buffer to a total particle volume of no less than 30%; (b) adding positively charged compounds or hydrophilic neutral compounds directly to the suspension of biological nanoparticles, or dissolving negatively charged compounds or hydrophobic compounds in helper lipids, such that the total volume of all the particles is no less than 30%; (c) incubating the obtained mixture; (d) extruding the mixture; (e) subsequently purifying the extrudate by gel exclusion chromatography. The result is that of widening the range of low molecular weight compounds that can be packed, allowing more efficient loading, and preserving the biological properties of micro- and nanoparticles after packing.
Resumen de: WO2026217662A1
Provided herein are methods of preparing a composition comprising an antibody-lipid nanoparticle conjugate, in which an antibody modified with a click chemistry ligand is introduced in-line following lipid nanoparticle formation and in-line dilution, ensuring homogeneous mixing and a favorable environment for antibody stability. Also provided herein are antibody-lipid nanoparticle conjugates prepared by such methods. Further provided herein are chips and instruments for use in preparing the antibody-lipid nanoparticle conjugate.
Resumen de: US20260315403A1
0000 An exosome-like nano vesicle formulation comprising: a neutral lipid; and at least three active ingredients selected from the group consisting of an extract, an osmolyte, and an antioxidant, and methods of use thereof, including methods of treating inflammation, increasing skin hydration, and reducing visible signs of aging in the skin.
Resumen de: WO2025192731A1
The present invention addresses the problem of providing: a compound or a salt thereof that is to constitute a lipid composition that makes it possible to achieve high expression of a protein when an mRNA is used and dose-responsive protein production when administered at a high dose; and a lipid composition, a pharmaceutical composition, and a delivery carrier that use the compound or salt thereof. The present invention provides a compound represented by formula (1) or a salt thereof. Each group in the formula is defined in the description.
Nº publicación: AU2025234040A1 15/10/2026
Solicitante:
THE UNIV OF MELBOURNE
THE UNIVERSITY OF MELBOURNE
Resumen de: AU2025234040A1
The present disclosure relates generally to nanoparticles and compositions comprising the same, and their use for transfecting transfection-recalcitrant cells, wherein the nanoparticle is tethered to an antigen-binding moiety having binding specificity for an antigen expressed on the surface of the cell, such as cluster of differentiation 2 (CD2) or cluster of differentiation 7 (CD7), wherein the nanoparticle comprises at least an ionisable lipid and a sterol.
BOPI
Sede Electrónica
